Facts and Figures


ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialises in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.

Headquarters

Dublin, Ireland

Financial Information

ICON’s revenues for FY ending 31 December 2017 was US$1.758 billion. ICON trades on the Nasdaq exchange.

Employee Numbers

ICON currently has 13,250 employees in 97 offices in 38 countries.

Products and Services

ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology and medical device companies to bring new treatments to market faster. Our services span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs.

  • Phase I-IV Clinical Trial Design, Management and Review
  • Clinical Pharmacology
  • Bioanalytical Laboratory Services
  • Clinical Pathology
  • Protocol Design
  • Biomarker Services
  • Pharmacodynamic/Pharmacokinetic Analysis
  • Data Management
  • Medical and Safety Services
  • Health Economics & Outcomes Research
  • Due diligence support
  • Payer Engagement Services
  • Consulting
  • Medical Device & Diagnostic Research
  • Patient and Investigator Portals
  • Biostatistics
  • Interactive Technologies – IVR, IWR, ePRO
  • Patient Recruitment
  • Medical Imaging
  • Global Central Laboratory Services
  • Medical Writing
  • Program Management
  • Contract Resourcing
  • Strategic Pricing
  • Market Access
  • Value Strategy
  • Adaptive Trials
  • Patient Centric Monitoring
  • eConsent

Key Company Milestones

  • 1990 -  ICON founded in Dublin, Ireland, by Dr. John Climax and Dr. Ronan Lambe
  • 1991 - ICON opens first overseas office in Winchester, UK
  • 1992 - ICON opens first US office in Philadelphia
  • 1996 - ICON opens first Asia-Pacific office in Japan
  • 1998 - ICON begins trading as a public company on the Nasdaq exchange
  • 1998 - ICON opens office in Singapore and Buenos Aries, Argentina
  • 2000 - ICON acquires UK-based regulatory consultancy
  • 2000 - ICON acquires Central Laboratory in New York
  • 2002 - ICON acquires Managed Clinical Solutions
  • 2003 - ICON acquires Medeval Group Ltd, a UK-based Phase I facility
  • 2003 - ICON acquires Globomax
  • 2004 - ICON acquires Beacon Bioscience Inc.
  • 2006 - ICON acquires Ovation
  • 2007 - ICON acquires DOCS International
  • 2007 - ICON Named “Favourite Contract Research Organisation” by pharmaceutical and biotech firms in independent survey by William Blair & Company and Thompson CenterWatch
  • 2008 - ICON acquires Healthcare Discoveries LLC
  • 2008 - ICON acquires Prevalere Life Sciences Inc
  • 2008 - ICON opens Central Laboratory in Bangalore, India
  • 2008 - ICON signs strategic agreement with Lilly to manage Lilly’s clinical Data Management business in over 36 countries
  • 2009 - ICON Recognised as Clinical Research Company of the year at the PharmaTimes Awards
  • 2009 - ICON opens new clinical pharmacology unit in Omaha, Nebraska, US
  • 2009 - ICON acquires Veeda Laboratories Ltd.
  • 2010 - ICON acquires Timaq Medical Imaging
  • 2011 - ICON acquires Oxford Outcomes Ltd.
  • 2011 - ICON acquires Firecrest Clinical Ltd.
  • 2011 - ICON acquires BeijingWits Medical Consulting Ltd
  • 2012 - ICON acquires PriceSpective LLC
  • 2013 - ICON acquires ClinForce and Assent Consulting, Staffing and FSP providers
  • 2013 - ICON acquires Akos an EU Provider of Pharmacovigilance and Drug Safety Services.
  • 2014 - ICON acquires Aptiv Solutions
  • 2015 - ICON creates new global innovation hub in Ireland to advance clinical development
  • 2015 - ICON acquires MediMedia Pharma Solutions
  • 2015 - ICON forms partnership with Mereo BioPharma for clinical development
  • 2015 - ICON acquires PMG Research Inc
  • 2016 - ICON acquires ClinicalRM
  • 2016 - ICON selected by Genomics England to support the world's largest genome sequencing project
  • 2016 - ICON selected by ICHOM to develop world’s first global healthcare outcomes benchmarking programme
  • 2017 - ICON Acquires Mapi Group